Medicaid prior-authorization programs and the use of cyclooxygenase-2 inhibitors.
about
Pharmaceutical policies: effects of restrictions on reimbursementState Medicaid programs did not make use of prior authorization to promote safer prescribing after rosiglitazone warningMedicaid prescription limits: policy trends and comparative impact on utilization.A blueprint for pharmacy benefit managers to increase valuePotential Savings from an Evidence-Based Consumer-Oriented Public Education Campaign on Prescription DrugsSystematic review on quality control for drug management programs: is quality reported in the literature?National patterns of codeine prescriptions for children in the emergency department.What doctors think about the impact of managed care tools on quality of care, costs, autonomy, and relations with patients.Evaluating the impact of a novel restricted reimbursement policy for quinolone antibiotics: a time series analysisThe impact of prior authorization on buprenorphine dose, relapse rates, and cost for Massachusetts Medicaid beneficiaries with opioid dependence.Adherence to prescribing recommendations made on a provincial formularyState generic substitution laws can lower drug outlays under Medicaid.Age and rising rates of cyclooxygenase-2 inhibitor use. Results from a national surveyWhen gatekeepers meet the sentinel: the impact of a prior authorization requirement for cefuroxime on the prescribing behaviour of community-based physiciansAngiotensin inhibition after myocardial infarction: does drug class matter?Implementation of cancer clinical care pathways: a successful model of collaboration between payers and providers.Prior authorization of newer insomnia medications in managed care: is it cost saving?The financial burden from prescription drugs has declined recently for the nonelderly, although it is still high for many.Impact of Medicaid prior authorization requirement for COX-2 inhibitor drugs in Nebraska.Drug reimbursement policies in Canada--need for improved access to critical therapies.Medicare Part D plan generosity and medication use among dual-eligible nursing home residents.Rationale and design of the Study Assessing the Effect of Cardiovascular Medications Provided as Low-cost, Evidence-based Generic Samples (SAMPLES) trial.Is there a relationship between patient beliefs or communication about generic drugs and medication utilization?Prior authorization for biologic disease-modifying antirheumatic drugs: a description of US Medicaid programs.Impact of two Medicaid prior-authorization policies on antihypertensive use and costs among Michigan and Indiana residents dually enrolled in Medicaid and Medicare: results of a longitudinal, population-based study.Medicaid cost control measures aimed at second-generation antipsychotics led to less use of all antipsychotics.Impact of prior authorization on the use and costs of lipid-lowering medications among Michigan and Indiana dual enrollees in Medicaid and Medicare: results of a longitudinal, population-based study.Impact of a health safety warning and prior authorisation on the use of piroxicam: a time-series study.Preapproval of sinus computed tomography for otolaryngologic evaluation of chronic rhinosinusitis does not save health care costs.Constraints on Formulary Design Under the Affordable Care Act.Trends in celecoxib and etoricoxib prescribing following removal of prior authorization requirement in Spain.Is Australia's national medicines policy failing? The case of COX-2 inhibitors.Potential savings in prescription drug costs for hypertension, hyperlipidemia, and diabetes mellitus by equivalent drug substitution in Austria: a nationwide cohort study.Impact of abuse-deterrent OxyContin on prescription opioid utilization.Medical and pharmacy expenditures after implementation of a cyclooxygenase-2 inhibitor prior authorization program.Adoption of Sacubitril/Valsartan for the Management of Patients With Heart Failure.Which physicians are affected most by Medicaid preferred drug lists for statins and antihypertensives?
P2860
Q24236533-DC7C4052-E9B9-4EF4-AB76-1D97CA828E12Q24604853-633B960D-3C0C-4C00-BD7A-B06E918AB9ABQ27306989-6F7BC1D5-787C-4FB4-9057-069C8D3E3716Q28766235-F147F350-8E1B-422B-9EB1-BB3F8E77F348Q29393270-0DCA984A-D30A-4F73-B374-D80FBED09AD4Q33412577-743E29D3-0744-4C30-9E9E-BDB14AF98185Q33551778-32340664-222C-44DB-99C4-53516240FD47Q33765244-A0713D46-C520-4761-BECA-68D7EA8EFEA1Q34398177-CC994691-FE76-482F-AA2B-D0EFDA7303D2Q34543555-B3DCD7AC-65BE-4989-B53F-78EB67F00A1EQ34598634-0256F15A-3E37-4CEB-ACEB-3F544FC13107Q35010316-81CD2BED-C622-4CC3-97B9-050A30964B63Q35688266-7A0EB0CE-ADAA-4105-8D2A-9289D81A49FEQ35827439-BFC1A2A8-10C1-4A04-AA00-1357CECDC8F5Q35901622-7CF435A8-15EE-4D98-B0F1-8563AD7E965BQ35947787-62B663D5-E83B-42A1-B420-8718D164B330Q35995325-0595D0BA-B468-4B51-AC88-43F7D1A65CF3Q36070889-A7F3A9BE-74BE-4062-8D0E-8FCDE49EA3F7Q36570328-8146D559-6939-4959-9F05-F633F85C35BCQ37162899-C8EF0CF2-7A4C-4319-8920-CAA2A0F4A315Q37171080-89D48456-5F66-4E22-AAA0-DB4C94A23203Q37196480-05FDF595-A9AC-43D7-80F7-C50A25103943Q37246833-204E42CC-1351-499D-9F81-7C7228503B66Q37314038-284A24B1-0966-4A9D-ADD9-0EC91B39B350Q37352239-78F793D6-8070-413C-9EAA-296CABC31F20Q37444777-60A374BC-871E-4A74-8853-799779333FF1Q37693536-C9C1409C-0A87-4418-BD2D-45A4C983B3DAQ37974880-1DC3EEF2-42A7-48B5-B6AC-F8641C2AA671Q38116496-B61EBFD7-01F0-49FA-8C85-1453761CDBB6Q38944596-671E86D6-166A-47A2-AA5D-8E6AF7FF5ABCQ39095394-A9BD50F1-5601-4DAD-BE6A-9F3FB1EE2631Q40145356-4CAB96FD-215B-4673-BBFE-6228CD4D0ADFQ41654265-C04294AB-0CE8-49B3-AA34-8BE1F4E7BEC7Q44348158-0F9CEC2E-FBA7-4419-B4DE-3767B638AC8BQ46592047-4619AE42-1328-46E8-B22D-A3976F56CB90Q49914014-D401E3E6-F312-4833-8C4C-6D10F688965BQ50179293-C3E846DE-0BB5-4AC7-9F2D-46BEE1A5A884
P2860
Medicaid prior-authorization programs and the use of cyclooxygenase-2 inhibitors.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Medicaid prior-authorization programs and the use of cyclooxygenase-2 inhibitors.
@ast
Medicaid prior-authorization programs and the use of cyclooxygenase-2 inhibitors.
@en
type
label
Medicaid prior-authorization programs and the use of cyclooxygenase-2 inhibitors.
@ast
Medicaid prior-authorization programs and the use of cyclooxygenase-2 inhibitors.
@en
prefLabel
Medicaid prior-authorization programs and the use of cyclooxygenase-2 inhibitors.
@ast
Medicaid prior-authorization programs and the use of cyclooxygenase-2 inhibitors.
@en
P2093
P356
P1476
Medicaid prior-authorization programs and the use of cyclooxygenase-2 inhibitors.
@en
P2093
Daniel H Solomon
Jerry Avorn
Michael A Fischer
Sebastian Schneeweiss
P304
P356
10.1056/NEJMSA042770
P407
P577
2004-11-01T00:00:00Z